| FORM PTO-1449 | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. P28509 | Application No. 10/549,816 |
|---|---|---|---|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant Makoto ASASHIMA et al. | |
| | | Filing Date I.A. Filed March 17, 2004 | Group Not Yet Known |

OIPE 1649 PATENT & TRADEMARK OFFICE

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| /KA/ | 2003 / | 0 1 0 9 0 3 5 | 06/12/03 | ASASHIMA et al. | | | |
| /KA/ | 2003 / | 0 1 9 1 3 4 2 | 10/09/03 | KAGECHIKA et al. | | | |
| /KA/ | 2005 / | 0 2 3 4 1 3 0 | 10/20/05 | NAGAI et al. | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| /KA/ | | 1 2 8 5 9 6 1 | 02/26/03 | E.P.O. | | | | |
| /KA/ | | 1 0 4 8 6 5 9 | 11/02/00 | E.P.O. | | | | |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | | |
|---|---|---|
| /KA/ | 1 | SEWTER C.P. et al., "Regional Differences in the Response of Human Pre-Adipocytes to PPARγ and RXRα Agonists", Diabetes (2002), vol. 51, No. 3, pp. 718-723. |
| | 2 | KIM M.J. et al., "Limited Cooperation between Peroxoisome Proliferator-Activated Receptors and Retinoid X Receptors Agonists in Sebocyte Growth and Development", Molecular Genetics and Metabolism (2001), vol. 74, No.3, pp. 362-369. |
| | 3 | MILLION K. et al., "Effects of Retinoic Acid Receptor-Selective Agonists on Human Nasal Epithelial Cell Differentiation" American Journal of Respiratory Cell and Molecular Biology (2001), vol. 25, No.6, pp. 744-750. |
| | 4 | SHIBAKURA M. et al., "A Retinoic Acid Receptor-α (RARα) Selective Agonist Modulates Procoagulant Activity of Acute Promyelocytic Cells and Induces Their Differentiation Into Neutrophils", Blood (1998), vol. 91, No. 2, pp. 724-725. |
| | 5 | WESTON A.D. et al., "Regulation of Skeletal Progenitor Differentiation by the BMP and Retinoid Signaling Pathways", The Journal of Cell Biology (2000), vol. 148, No. 4, pp. 679-690. |
| | 6 | NAGY L. et al., "Activation of Retinoid X Receptors Induces Apoptosis in HL-60 Cell Lines", Molecular and Cellular Biology (1995), vol. 15, No. 7, pp. 3540-3551. |
| | 7 | ISHIDA S. et al., "Clinically Potential Subclasses of Retinoid Synergists Revealed by Gene Expression Profiling", Molecular Cancer Therapeutics (2003), vol. 2, no. 1, pp. 49-58. |
| | 8 | TAKAHASHI B. et al., "Novel Retinoid X Receptor Antagonists: Specific Inhibition of Retinoid Synergism in RXR-RAR Heterodimer Actions", Journal of Medicinal Chemistry (2002), vol. 45, no. 16, pp. 3327-3330. |
| | 9 | HONDA M. et al., "RXR agonist enhances the differentiation of cardiomyocytes derived from embryonic stem cells in serum-free conditions", Biochemical and Biophysical Research Communications (2005), vol. 333, no. 4, pp. 1334-1340. |
| | 10 | COLLINS S.J., "The HL-60 Promyelocytic Leukemia Cell Line: Proliferation, Differentiation, and Cellular Oncogene Expression", Blood (1987), vol. 70, no. 5, pp. 1233-1244. |
| | 11 | MONTESANO R. et al., "Retinoids induce lumen morphogenesis in mammary epithelial cells", Journal of Cell Science (2002), vol. 115, no. 23, pp. 4419-4431. |
| | 12 | RAZ Y. et al. "Retinoic Acid Signaling is Necessary for the Development of the Organ of Corti", Developmental Biology (1999), vol. 213, no. 1, pp. 180-193. |
| | 13 | TRAN C.M. et al., "The RXRα gene functions in a non-cell-autonomous manner during mouse cardiac morphogenesis", Development (1998), vol. 125, no. 10, pp. 1951-1956. |
| | 14 | U.S. Application No. 11/366,454 to NAGAI et al., filed March 3, 2006 and entitled "MEDICAMENT HAVING PROMOTING ACTION ON NEOVASCULARIZATION". |

| EXAMINER | /Kade Ariani/ | DATE CONSIDERED | 04/28/2008 |
|---|---|---|---|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.